Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. For more information, go to: www.fujifilmdiosynth.com. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Actively contributed and participated in the acquisition of Atara Biotherapeutics. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). achapman@atarabio.com, View this news release online at: Alex Chapman With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. The collective expertise of the team will further support our efforts as a world-class CDMO, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Watertown, MA 02472 achapman@atarabio.com, Atara Moffitt Cancer Center FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. We believe that now is the right time for a strategic relationship with FDB to provide us with expert manufacturing capabilities, as needed. The parties will also enter a long-term supply agreement, which could extend to ten years. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Eric Hyllengren Fujifilm Expands its Advanced Therapies CDMO Business with the Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress. Leading Global rewards project planning and execution. 2022-04-04 TOKYO, April 4, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million.
Dupage County Mugshots 2020,
Are Axolotls Legal In Connecticut,
Edit Distance Recursive,
Do School Districts Drug Test Employees 2020,
Articles A